ACF Equity Research says Chinese control of Rare Earths production is a ‘global strategic concern’.  Watch the video here.

Less Ads, More Data, More Tools Register for FREE

MaxCyte inks deal with South Korea's Curamys

Mon, 05th Dec 2022 13:28

(Sharecast News) - Cell engineering technology company MaxCyte announced a strategic platform licence with South Korea-based biotechnology specialist Curamys on Monday, which develops cell and gene therapies using cell fusion technology to treat rare intractable diseases, including Duchenne muscular dystrophy and amyotrophic lateral sclerosis.

The AIM-traded firm said that under the deal, Curamys would obtain non-exclusive clinical and commercial rights to use MaxCyte's 'Flow Electroporation' technology and 'ExPERT' platform.

In return, MaxCyte would receive platform licensing fees and programme-related revenue.

The board said Curamys is focussed on developing treatments for genetic and degenerative diseases through its specialised cell fusion technology, based on the concept that apoptotic or dying cells could be regenerated by fusing them with healthy, "normal" cells.

Cell fusion technology can function as a form of gene therapy when the normal copies of genes existing in treatment cells are transferred to dying cells, resulting in the development of treatments for genetic and rare intractable diseases at the cellular level.

"A recent report estimates that there are more than 10,000 distinct rare diseases affecting 400 million people around the world," said president and chief executive officer Doug Doerfler.

"Many of these diseases, like ALS and DMD, have few or no treatments.

"We are honoured to support Curamys' efforts to develop its cell-fusion technology for novel cell-based treatments that provide hope and new options to patients and their families."

At 1222 GMT, shares in MaxCyte were up 1.63% in London, at 500p.

Reporting by Josh White for

Related Shares

More News
16 Nov 2023 13:57

MaxCyte joins Alliance for mRNA Medicines

(Sharecast News) - Cell engineering company MaxCyte announced its membership in the Alliance for mRNA Medicines (AMM) as a founding member on Thursday...

9 Nov 2023 14:14

EARNINGS AND TRADING: Chapel Down hopes to make splash on AIM

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately report...

1 Nov 2023 15:44

UK earnings, trading statements calendar - next 7 days

5 Oct 2023 13:00

MaxCyte lowers full-year guidance after weaker third quarter

(Sharecast News) - Cell engineering specialist MaxCyte revised its full-year guidance downwards on Thursday based on its preliminary third-quarter rev...

5 Oct 2023 10:16

AIM WINNERS & LOSERS: SDX Energy receives gas prepayment from Citic

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.